Morphabond Er

Pain, Therapeutic procedure, Chronic Pain
Treatment
2 FDA approvals
20 Active Studies for Morphabond Er

What is Morphabond Er

MorphineThe Generic name of this drug
Treatment SummaryMorphine is a strong pain reliever, first extracted from poppy plants in 1805. It is still used today to treat severe pain, however other medications such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone are often used as alternatives due to the risks associated with morphine use (tolerance, withdrawal, and abuse). Morphine was officially approved by the FDA in 1941.
Morphine Sulfateis the brand name
Morphabond Er Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Morphine Sulfate
Morphine
1971
458

Approved as Treatment by the FDA

Morphine, otherwise known as Morphine Sulfate, is approved by the FDA for 2 uses including Chronic Pain and Pain .
Chronic Pain
Helps manage Pain, Chronic
Pain

Effectiveness

How Morphabond Er Affects PatientsMorphine blocks pain signals from reaching the brain, which helps reduce pain. Its effects can take anywhere from 6-30 minutes to kick in. Taking too much morphine and other opioids can cause permanent changes in the brain. Morphine works differently in men and women, with women needing less of it to feel the same effects. Morphine-6-glucuronide is much weaker than morphine when it comes to constricting the pupils.
How Morphabond Er works in the bodyMorphine-6-glucuronide is the primary chemical responsible for the effects of morphine. It binds to two types of opioid receptors: mu and kappa. The mu-opioid receptor is responsible for morphine's effects on the brain's reward system, breathing, and addiction. The kappa-opioid receptor helps with pain relief.

When to interrupt dosage

The suggested dosage of Morphabond Er is founded on the diagnosed condition, including Therapeutic procedure, Pain and Chronic Pain. The amount additionally alters as per the method of delivery exemplified in the table below.
Condition
Dosage
Administration
Therapeutic procedure
0.1 mg/mL, 10.0 mg, 50.0 mg/mL, 70.0 mg, 1.0 mg/mL, 5.0 mg/mL, 1.1 mg/mL, 40.0 mg, 130.0 mg, 150.0 mg, 15.0 mg, 60.0 mg, , 0.5 mg/mL, 2.0 mg/mL, 100.0 mg, 80.0 mg, 100.0 mg/mL, 8.0 mg/mL, 4.0 mg/mL, 25.0 mg, 5.0 mg, 10.0 mg/mL, 200.0 mg, 50.0 mg, 30.0 mg, 90.0 mg, 20.0 mg, 40.0 mg/mL, 20.0 mg/mL, 120.0 mg, 15.0 mg/mL, 25.0 mg/mL, 3.0 mg/mL, 45.0 mg, 75.0 mg
, Injection, solution - Intravenous; Subcutaneous, Injection, Injection, solution - Epidural; Intrathecal, Oral, Tablet, Capsule, extended release, Injection - Intravenous, Injection, solution - Intravenous, Injection, solution - Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid, Solution, Intrathecal; Intravenous, Epidural; Intrathecal, Syrup - Oral, Solution - Intravenous; Subcutaneous, Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release - Oral, Suppository, Solution - Epidural; Intravenous; Subcutaneous, Capsule, coated, extended release, Epidural; Intravenous; Subcutaneous, Rectal, Suppository - Rectal, Intravenous, Injection, solution, concentrate, Tablet, multilayer, extended release, Capsule, Epidural; Intramuscular; Intrathecal; Intravenous, Injection, solution, Intramuscular, Suppository, extended release - Rectal, Epidural, Capsule - Oral, Tablet, extended release, Injection - Epidural; Intrathecal, Solution - Epidural, Intravenous; Subcutaneous, Capsule, coated, extended release - Oral, Tablet, film coated - Oral, Injection - Epidural; Intrathecal; Intravenous, Liquid, Solution - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, extended release, Tablet, multilayer, extended release - Oral, Injection, solution - Epidural; Intrathecal; Intravenous, Injection - Intramuscular, Epidural; Intrathecal; Intravenous, Syrup, Tablet, film coated, Injection, solution - Intramuscular; Intravenous, Solution / drops - Oral, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution - Oral, Intramuscular; Intravenous, Tablet, film coated, extended release - Oral, Solution, concentrate - Oral, Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid, Injection, lipid complex - Epidural, Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, solution - Epidural; Intramuscular; Intrathecal; Intravenous, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intravenous, Suppository, extended release, Intrathecal, Solution, concentrate, Injection, lipid complex, Tincture, Injection, solution - Intrathecal, Liquid - Oral, Solution - Intravenous, Solution / drops, Liquid - Intravenous; Subcutaneous, Injection - Parenteral, Injection, solution - Intrathecal; Intravenous, Tincture - Oral, Injection, solution, concentrate - Intravenous
Pain
0.1 mg/mL, 10.0 mg, 50.0 mg/mL, 70.0 mg, 1.0 mg/mL, 5.0 mg/mL, 1.1 mg/mL, 40.0 mg, 130.0 mg, 150.0 mg, 15.0 mg, 60.0 mg, , 0.5 mg/mL, 2.0 mg/mL, 100.0 mg, 80.0 mg, 100.0 mg/mL, 8.0 mg/mL, 4.0 mg/mL, 25.0 mg, 5.0 mg, 10.0 mg/mL, 200.0 mg, 50.0 mg, 30.0 mg, 90.0 mg, 20.0 mg, 40.0 mg/mL, 20.0 mg/mL, 120.0 mg, 15.0 mg/mL, 25.0 mg/mL, 3.0 mg/mL, 45.0 mg, 75.0 mg
, Injection, solution - Intravenous; Subcutaneous, Injection, Injection, solution - Epidural; Intrathecal, Oral, Tablet, Capsule, extended release, Injection - Intravenous, Injection, solution - Intravenous, Injection, solution - Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid, Solution, Intrathecal; Intravenous, Epidural; Intrathecal, Syrup - Oral, Solution - Intravenous; Subcutaneous, Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release - Oral, Suppository, Solution - Epidural; Intravenous; Subcutaneous, Capsule, coated, extended release, Epidural; Intravenous; Subcutaneous, Rectal, Suppository - Rectal, Intravenous, Injection, solution, concentrate, Tablet, multilayer, extended release, Capsule, Epidural; Intramuscular; Intrathecal; Intravenous, Injection, solution, Intramuscular, Suppository, extended release - Rectal, Epidural, Capsule - Oral, Tablet, extended release, Injection - Epidural; Intrathecal, Solution - Epidural, Intravenous; Subcutaneous, Capsule, coated, extended release - Oral, Tablet, film coated - Oral, Injection - Epidural; Intrathecal; Intravenous, Liquid, Solution - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, extended release, Tablet, multilayer, extended release - Oral, Injection, solution - Epidural; Intrathecal; Intravenous, Injection - Intramuscular, Epidural; Intrathecal; Intravenous, Syrup, Tablet, film coated, Injection, solution - Intramuscular; Intravenous, Solution / drops - Oral, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution - Oral, Intramuscular; Intravenous, Tablet, film coated, extended release - Oral, Solution, concentrate - Oral, Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid, Injection, lipid complex - Epidural, Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, solution - Epidural; Intramuscular; Intrathecal; Intravenous, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intravenous, Suppository, extended release, Intrathecal, Solution, concentrate, Injection, lipid complex, Tincture, Injection, solution - Intrathecal, Liquid - Oral, Solution - Intravenous, Solution / drops, Liquid - Intravenous; Subcutaneous, Injection - Parenteral, Injection, solution - Intrathecal; Intravenous, Tincture - Oral, Injection, solution, concentrate - Intravenous
Chronic Pain
0.1 mg/mL, 10.0 mg, 50.0 mg/mL, 70.0 mg, 1.0 mg/mL, 5.0 mg/mL, 1.1 mg/mL, 40.0 mg, 130.0 mg, 150.0 mg, 15.0 mg, 60.0 mg, , 0.5 mg/mL, 2.0 mg/mL, 100.0 mg, 80.0 mg, 100.0 mg/mL, 8.0 mg/mL, 4.0 mg/mL, 25.0 mg, 5.0 mg, 10.0 mg/mL, 200.0 mg, 50.0 mg, 30.0 mg, 90.0 mg, 20.0 mg, 40.0 mg/mL, 20.0 mg/mL, 120.0 mg, 15.0 mg/mL, 25.0 mg/mL, 3.0 mg/mL, 45.0 mg, 75.0 mg
, Injection, solution - Intravenous; Subcutaneous, Injection, Injection, solution - Epidural; Intrathecal, Oral, Tablet, Capsule, extended release, Injection - Intravenous, Injection, solution - Intravenous, Injection, solution - Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid, Solution, Intrathecal; Intravenous, Epidural; Intrathecal, Syrup - Oral, Solution - Intravenous; Subcutaneous, Capsule, extended release - Oral, Tablet - Oral, Tablet, extended release - Oral, Suppository, Solution - Epidural; Intravenous; Subcutaneous, Capsule, coated, extended release, Epidural; Intravenous; Subcutaneous, Rectal, Suppository - Rectal, Intravenous, Injection, solution, concentrate, Tablet, multilayer, extended release, Capsule, Epidural; Intramuscular; Intrathecal; Intravenous, Injection, solution, Intramuscular, Suppository, extended release - Rectal, Epidural, Capsule - Oral, Tablet, extended release, Injection - Epidural; Intrathecal, Solution - Epidural, Intravenous; Subcutaneous, Capsule, coated, extended release - Oral, Tablet, film coated - Oral, Injection - Epidural; Intrathecal; Intravenous, Liquid, Solution - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Tablet, film coated, extended release, Tablet, multilayer, extended release - Oral, Injection, solution - Epidural; Intrathecal; Intravenous, Injection - Intramuscular, Epidural; Intrathecal; Intravenous, Syrup, Tablet, film coated, Injection, solution - Intramuscular; Intravenous, Solution / drops - Oral, Liquid - Intramuscular; Intravenous; Subcutaneous, Solution - Oral, Intramuscular; Intravenous, Tablet, film coated, extended release - Oral, Solution, concentrate - Oral, Epidural; Intraspinal; Intrathecal; Intravenous; Subarachnoid, Injection, lipid complex - Epidural, Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, solution - Epidural; Intramuscular; Intrathecal; Intravenous, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intravenous, Suppository, extended release, Intrathecal, Solution, concentrate, Injection, lipid complex, Tincture, Injection, solution - Intrathecal, Liquid - Oral, Solution - Intravenous, Solution / drops, Liquid - Intravenous; Subcutaneous, Injection - Parenteral, Injection, solution - Intrathecal; Intravenous, Tincture - Oral, Injection, solution, concentrate - Intravenous

Warnings

Morphabond Er has six contraindications, so it must not be simultaneously taken with any of the conditions in the table below.Morphabond Er Contraindications
Condition
Risk Level
Notes
Mental Depression
Do Not Combine
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
Gastrointestinal obstruction
Do Not Combine
Asthma
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Morphine may interact with Toxoplasma Infections
There are 20 known major drug interactions with Morphabond Er.
Common Morphabond Er Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Morphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Morphine.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Morphine.
Eluxadoline
Major
The risk or severity of constipation can be increased when Morphine is combined with Eluxadoline.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Morphine.
Morphabond Er Toxicity & Overdose RiskThe toxic dose of this drug is 0.78 micrograms per milliliter for males and 0.98 micrograms per milliliter for females. An overdose can cause difficulty breathing, drowsiness, limp muscles, cold and clammy skin, constricted pupils, and dilated pupils. Severe symptoms may include fluid buildup in the lungs, slow heartbeat, low blood pressure, heart failure, and even death. Treatment of an overdose involves providing oxygen, medications to raise blood pressure, and a medicine called naloxone.

Morphabond Er Novel Uses: Which Conditions Have a Clinical Trial Featuring Morphabond Er?

24 active clinical trials are currently being conducted to assess the potential of Morphabond Er in providing therapeutic intervention, alleviating Pain and ameliorating Chronic Pain.
Condition
Clinical Trials
Trial Phases
Pain
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Chronic Pain
27 Actively Recruiting
Phase 3, Not Applicable, Phase 2

Morphabond Er Reviews: What are patients saying about Morphabond Er?

4.3Patient Review
11/20/2018
Morphabond Er for Chronic Pain
Though I follow the prescribed dosage, these pills do nothing for me in terms of relief. All they do is make me feel like I'm sweating all the time.
2.3Patient Review
9/10/2019
Morphabond Er for Chronic Pain
I was pretty disappointed with this treatment. It didn't work nearly as well as my usual, generic brand. I think it releases too slowly over too long of a time compared to the other. I now constantly feel pain and need more medication.

Patient Q&A Section about morphabond er

Can MS Contin 15 mg ER be crushed?

"You should swallow MS Contin tablets whole, and not break, chew, dissolve or crush them." - Anonymous Online Contributor

Unverified Answer

Can you crush morphine sulfate immediate release?

"Take morphine sulfate extended-release tablets as a whole. Do not cut, break, chew, crush, dissolve, snort, or inject morphine sulfate extended-release tablets as this can lead to an overdose and death." - Anonymous Online Contributor

Unverified Answer

What is MST analgesic?

"MST Continus is a medication used to relieve severe pain over a period of 12 hours. It contains the active ingredient morphine which belongs to a group of medicines called strong analgesics or 'painkillers'." - Anonymous Online Contributor

Unverified Answer

What is Morphabond used for?

"Morphabond is a Morphine Sulfate that is used to treat the symptoms of Acute Pain and Chronic Severe Pain. It may be used alone or with other medications." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Morphabond Er

Image of Northwestern University in Chicago, United States.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

Education + Online Pain Coping Skill Trainingfor Joint Pain

Chicago, IL
18+
Female
The main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are taking an AI medication, and who have arthralgia. Arthralgia is a type of joint, bone, and muscle pain that is a common side effect of AI medications. The main questions it aims to answer are: Whether online pain coping skills training reduces the severity of pain and the interference it causes in women's daily lives. Whether online pain coping skills training improves emotional distress, quality of life, and adherence to AI medications. Whether benefits of online pain coping skills training are at least partially caused by women's increased confidence that they can manage their pain and a reduction in unhelpful thinking patterns about pain. Whether online pain coping skills training improves effects of AI medications on sleep problems and symptoms of menopause like hot flashes and night sweats. Participants can complete all parts of the study at home. They will: Complete four sets of questionnaires throughout the study, which will take about 9 to 10 months. Attend 3 meetings in the first month of the study, all of which can be held via a video conference. Use an electronic pill bottle to track their use of their AI medication. Be randomized (like flipping a coin) to one of two study arms: They will either receive education about AIs and arthralgia or they will receive this education along with access to an online pain coping skills training program. Research will compare the education group to the education plus online pain coping skills training group to see if online pain coping skills training has the benefits mentioned above.
Phase 3
Recruiting
Northwestern University (+1 Sites)
Image of VA Boston Healthcare System in Boston, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Tai Chi Groupfor Chronic Pain

Boston, MA
18+
All Sexes
In the proposed trial, the investigators plan to refine interventions, then conduct a small randomized trial to provide critical information to inform a future large-scale randomized efficacy trial of Tai Chi for Post Traumatic Stress Disorder (PTSD) and chronic pain. Building on the combined experience the proposed study will progress in new directions to: Adapt, refine, and standardize two 12-week treatment protocols (Tai Chi and a Wellness control condition) for Veterans diagnosed with PTSD and chronic musculoskeletal pain during Phase One. Tai Chi and Wellness interventions will be adapted for delivery via a videoconferencing platform for the population and piloted in a 'dry run'. Determine the feasibility and acceptability of a remotely delivered randomized trial of these two interventions and the assessment protocols during Phase Two. Utilize information from this trial to plan and design a large randomized control study evaluating the efficacy of Tai Chi compared to Wellness for improving outcomes for Veterans with PTSD and chronic musculoskeletal pain.
Waitlist Available
Has No Placebo
VA Boston Healthcare SystemBarbara L Niles, PhD
Image of Massachusetts General Hospital Cancer Center in Boston, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Sub-study A: Siltuximabfor Schwannomatosis

Boston, MA
18+
All Sexes
This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). This Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies: Investigational Drug Sub-Study A: Siltuximab Investigation Drug Sub-Study B: Erenumab-Aooe
Phase 2
Waitlist Available
Massachusetts General Hospital Cancer CenterScott Plotkin, MDRecordati Rare Diseases
Image of Centre de recherche sur le vieillissement (CdRV) in Sherbrooke, Canada.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Actual TDCSfor Chronic Pain

Sherbrooke, Canada
65+
All Sexes
The primary objective of this study is to determine, in a healthcare setting, the effectiveness of actual tDCS in reducing pain compared with placebo tDCS. This is a multicenter randomized controlled trial with parallel groups (real tDCS vs. placebo) blinded to participants, assessors and tDCS providers. The real tDCS group will receive a daily 20-minute session of tDCS (current intensity = 2 mA), for 5 consecutive days, while the placebo tDCS group will receive an equivalent treatment, but the current will be stopped after the first 30 seconds. The study will take place in 5 rehabilitation clinics in 3 Quebec regions. One hundred and fifty (150) seniors aged 65 years or older with chronic (> 6 months), moderate to severe musculoskeletal pain will be recruited (50 participants/region). Follow-ups will take place at 1 week and 3 months post-treatment. The primary dependent variable is pain intensity (numerical scale from 0 to 10). Secondary variables will be measured using standardized and validated questionnaires: 1) pain-related interferences (physical function, mood, quality of life) and 2) perception of post-TDCS changes. Neurophysiological measures (pain control pathways).
Waitlist Available
Senior-friendly
Centre de recherche sur le vieillissement (CdRV)Guillume Léonard
Have you considered Morphabond Er clinical trials? We made a collection of clinical trials featuring Morphabond Er, we think they might fit your search criteria.
Have you considered Morphabond Er clinical trials? We made a collection of clinical trials featuring Morphabond Er, we think they might fit your search criteria.
Image of Hospital for Sick Children in Toronto, Canada.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Custom VR (Modified PR-VR Program + Usual Care)for Chronic Pain

Toronto, Canada
12 - 18
All Sexes
Poorly controlled chronic pain in teens can impact quality of life, increase opioid use and is a risk factor for developing chronic pain in adulthood. Currently, there is a shortage of support to help teens manage chronic pain in the community and the support that did exist has been significantly scaled back due to the COVID-19 pandemic. This research study will investigate, based on questionnaires with teens and healthcare providers and interviews with teens, whether pain rehabilitation virtual reality is easy to use and understand, satisfactory to use, and whether it may improve pain, mobility, and function for the teens using the program compared to those doing standard physiotherapy treatment over videoconference.
Recruiting
Has No Placebo
Hospital for Sick ChildrenJennifer Stinson, RN, PhD
Have you considered Morphabond Er clinical trials? We made a collection of clinical trials featuring Morphabond Er, we think they might fit your search criteria.